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Lung interstitial CD4+ T cells are critical for protec-
tion against pulmonary infections, but the fate of
this population during HIV-1 infection is not well
described. We studied CD4+ T cells in the setting
of HIV-1 infection in human lung tissue, humanized
mice, and a Mycobacterium tuberculosis (Mtb)/sim-
ian immunodeficiency virus (SIV) nonhuman primate
co-infection model. Infection with a CCR5-tropic
strain of HIV-1 or SIV results in severe and rapid
loss of lung interstitial CD4+ T cells but not blood
or lung alveolar CD4+ T cells. This is accompanied
by high HIV-1 production in these cells in vitro and
in vivo. Importantly, during early SIV infection, loss
of lung interstitial CD4+ T cells is associated with
increased dissemination of pulmonaryMtb infection.
We show that lung interstitial CD4+ T cells serve as
an efficient target for HIV-1 and SIV infection that
leads to their early depletion and an increased risk
of disseminated tuberculosis.
INTRODUCTION
HIV-1 infection results in loss of circulating CD4+ T cells, but only
after years of untreated infection (Okoye and Picker, 2013).
Investigation of HIV-1 and simian immunodeficiency virus (SIV)
revealed severe CD4+ T cell depletion in the gut early after infec-
tion before significant loss of cells in the circulation or secondary
lymph nodes (Brenchley et al., 2004; Li et al., 2005). Several
studies have examined the effect of HIV-1 on lung CD4+
T cells obtained from bronchoalveolar lavage (BAL) as a method
to sample the alveolar space as a proxy for the lung parenchyma.
These studies reported minimal to no CD4+ T cell loss during
acute or chronic HIV-1 infection in the alveolar space. This may
in part be due to concomitant HIV-1-induced lymphocyte alveo-
litis, which could partially compensate for CD4+ T cell loss
(Brenchley et al., 2008; Bunjun et al., 2017; Knox et al., 2010;
Neff et al., 2015). Few studies have examined human lung inter-
stitial CD4+ T cells, which are distinct from those in the alveolar
space and are believed to be critical for providing protection
against respiratory infections such as influenza and tuberculosis
(TB) (Sakai et al., 2014; Zens et al., 2016). Because of the diffi-
culty of assessing lung interstitial CD4+ T cells, our understand-
ing of the effect of HIV-1 infection on this population of protective
tissue-resident cells remains incomplete.
Mucosal CD4+ T cells constitute a large reservoir of HIV-1
target cells because of their high baseline activation state and
expression of the HIV-1 entry co-receptor CCR5. HIV-1 strains
that use CCR5 (CCR5-tropic) are primarily responsible for the
establishment of infection and generally predominate until devel-
opment of late-stage disease (Okoye and Picker, 2013). In
contrast, the appearance of HIV-1 strains that use the co-recep-
tor CXCR4 (CXCR4-tropic) is associated with progression to
AIDS and depletion of CXCR4-expressing memory CD4+
T cells in secondary lymphoid organs (SLOs) (Doitsh et al.,
2014; Penn et al., 1999). Lung CD4+ T cells express both
CCR5 and CXCR4 (Purwar et al., 2011), but the susceptibility
of these cells to HIV-1 and subsequent cell death have not
been well characterized. This is particularly important because
increased susceptibility to some respiratory infections, such as
Mycobacterium tuberculosis (Mtb), has been reported early in
HIV-1 disease, before systemic immune impairment is evident
(Diedrich and Flynn, 2011).
Animal models of human pulmonary Mtb infection have iden-
tified a key role for CD4+ T cells in protecting against active TB
(ATB) (Mogues et al., 2001). HIV-1 co-infection increases the
risk for ATB by 20- to 40-fold (Lawn and Zumla, 2011), with
high rates of extrapulmonary disseminated TB associated
with unfavorable treatment outcomes and high mortality rates
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(Kerkhoff et al., 2017). The risk for ATB generally correlates with
the decrease in circulating CD4+ T cells (Lawn and Zumla, 2011;
Sonnenberg et al., 2005). However, early in HIV-1 infection, indi-
viduals are at increased risk of ATB before significant loss of pe-
ripheral CD4+ T cells, suggesting that loss of CD4+ T cells in the
circulation may not entirely reflect their depletion at the site of
Mtb infection in the lung (Kerkhoff et al., 2017; Sonnenberg
et al., 2005). Tissue-resident memory-like (TRM-like) CD4+
T cells in the lung interstitium have a higher protective capacity
against TB than Mtb-specific T cells in the circulation (Sallin
et al., 2017). Whether HIV-1 infection results in depletion of pro-
tective CD4+ T cells in the lung interstitium and whether this
is associated with HIV-1-induced susceptibility to active or
disseminated TB is not well characterized.
We show that HIV-1 infection induces severe and early CD4+
T cell depletion in the lung interstitium using ex vivo infection of
human CD4+ T cells from lung tissue and in vivo HIV-1 infection
in a humanized mouse model. In contrast, alveolar CD4+ T cell
numbers are only marginally affected by HIV-1 infection. We
further demonstrate that early loss of lung interstitial, but not
alveolar, CD4+ T cells during SIV infection of nonhuman primates
(NHPs) is associated with dissemination of Mtb to extrapulmo-
nary organs during latent TB infection (LTBI). These findings indi-
cate that lung interstitial CD4+ T cell loss during early lentiviral
infection is significantly underestimated by sampling of the alve-
olar space and that loss of these cells may contribute to the
increased risk of Mtb dissemination seen in those with early
HIV-1 infection.
RESULTS
CCR5-Tropic HIV-1 Induced Severe Depletion of Human
Lung CD4+ T Cells
We examined lymphocytes collected from human lungs, tonsils,
and blood for CD4+ T cell phenotypes and HIV-1 co-receptor
expression. Consistent with other reports, CD4+ T cells in human
lungs and tonsils were enriched for CD69+CD45RO+CD62L
TRM-like cells (Figure 1A; Kumar et al., 2017; Mahnke et al.,
2013). However, only lung memory CD4+ T cells demon-
strated high expression levels of the HIV-1 co-receptor CCR5
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Figure 1. CCR5-Tropic HIV-1 Infection Induced Severe Depletion of Human Lung CD4+ T Cells
Single-cell suspensions were obtained from human lung, tonsil, and blood samples.
(A and B) The frequency of (A) TRM-like CD4+ cells (TCRa/b+CD45RO+CD62LCD25CD69+) and (B) HIV-1 co-receptor CCR5+ memory CD4+ T cells was
determined by flow cytometry.
(C–F) 0.5 3 106 cells were cultured in a V-bottom 96-well plate, and, where indicated, cells were incubated with antiretroviral (ARV) drugs (DRV, darunavir
[a protease inhibitor]; RAL, raltegravir [an integrase inhibitor]; AZT, zidovudine [a reverse transcriptase (RT) inhibitor]; EFV, efavirenz [an RT inhibitor]; MVC,
maraviroc [a CCR5 antagonist]) before infection with CCR5-tropic NL4-3 GFP HIV-1 and analyzed by flow cytometry.
(C) The percentage of viable CD4+ T cells was determined relative to untreated cells.
(D) The percentage of productively infected CD4+ T cells was determined by analyzing HIV-1 GFP+ CD4+ T cells.
(E) Correlation between percentage of viable CD4+ T cell and productively infected cells.
(F) Percentage of viable CD4+ T cells in mock-infected, HIV-1-infected, and HIV-1-infected samples pre-incubated with different ARVs.
The p values weremeasured by (A–D and F) Kruskal-Wallis and Dunn’smultiple comparisons tests or (E) by Spearman r test. Scatterplots are labeled withmedian
and interquartile range. Each data point represents the average of duplicates from one subject.
See also Figure S1.
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(Figure 1B). Given the high frequency of CCR5+ TRM-like cells in
the lung, we surmised that these cells would be highly suscepti-
ble to CCR5-tropic HIV-1 infection. We infected lung-, blood-,
and tonsil-derived lymphocytes with CCR5-tropic HIV-1 encod-
ing a GFP reporter and analyzed the frequency of infected cells.
For human lung tissue, we observed a significant decrease in
viable CD4+ T cells (Figure 1C; Figure S1A) but not CD8+
T cells (Figure S1B), accompanied by a higher frequency of
HIV-1 CCR5-tropic-infected CD4+ T cells compared with tonsils
and peripheral blood mononuclear cells (PBMCs) (Figure 1D).
Viral replication and the loss of viable CD4+ T cells were depen-
dent on HIV-1 co-receptor-mediated entry because the CCR5
receptor antagonist maraviroc inhibited CD4+ T cell loss and
viral replication (Figures 1C and 1D). In contrast, tonsil CD4+
T cells were more susceptible to productive infection and deple-
tion by a CXCR4-tropic virus (Figures S1C and S1D). Following
in vitro infection, the decrease in viable CD4+ T cells correlated
with the frequency of productively infected HIV-1 CCR5-tropic
GFP+ CD4+ T cells (Figure 1E). Next we investigated viral
functions required to induce significant cell loss by testing
antiretrovirals (ARVs) that target different stages of the HIV-1
life cycle. The protease inhibitor darunavir (DRV), the integrase
inhibitor raltegravir (RAL), the nucleoside analog reverse tran-
scriptase (RT) inhibitor zidovudine (AZT), the non-nucleoside
analog RT inhibitor efavirenz (EFV), and the viral entry inhibitor
maraviroc (MVC) were all able to reduce HIV-1-induced CD4+
T cell loss with no significant difference in viable CD4+ T cells
compared with mock-infected controls (Figures 1F and S1E).
Productive HIV-1 infection has been reported to induce cas-
pase-3-dependent cell death, whereas abortive infection in-
duces caspase-1 or inflammasome-mediated pyroptosis (Doitsh
et al., 2014; Jekle et al., 2003). The pan caspase inhibitor Z-VAD
and the caspase-3 inhibitor Z-DEVD fully rescued HIV-1-induced
CD4+ T cell loss, whereas the caspase-1 inhibitor had no effect
(Figure S1F). Likewise, CCR5-tropic HIV-1 induced secretion of
the pro-inflammatory cytokine CXCL10 but not the caspase-1
or inflammasome-induced cytokine interleukin-1b (IL-1b) (Fig-
ures S1G and S1I). Together, our data indicate that lung CD4+
T cells are highly permissive to productive viral infection with
CCR5-tropic HIV-1, which caused rapid caspase-3-mediated
CD4+ T cell death in human lung tissue.
Lung Interstitial CD4+ T Are Cells Severely Depleted
during Acute HIV-1 Infection In Vivo
Our ex vivo experiments with human lung tissue indicated that
lung CD4+ T cells are more affected by HIV-1 than previously
estimated from studies of human BAL (Bunjun et al., 2017).
The humanized mouse has been used to study early HIV-1
infection in tissue and, therefore, offered an opportunity to
investigate depletion of BAL and lung interstitial CD4+ T cells
following HIV-1 infection in vivo (Deruaz et al., 2017). Human-
ized mice were challenged intravaginally with CCR5-tropic
HIV-1 JR-CSF or saline control. Lung CD4+ T cells were char-
acterized 4 and 7 weeks after infection, at stages that reflect
acute and early chronic HIV-1 infection, respectively (Dudek
and Allen, 2013; Dudek et al., 2012; McMichael et al., 2010).
CD4+ T cells were only significantly depleted in the lung inter-
stitium, where they were reduced by 6.6-fold at week 7 (Figures
2A–2D). This depletion was significantly higher compared with
paired BAL samples at week 4 and week 7 (Figures 2E and
2F). In BAL samples, we observed a trend for increased BAL
CD8+ T cell numbers, with a significantly higher fold increase
of BAL CD8+ T cells from HIV+ humanized mice at weeks 4
and 7 compared with paired lung interstitial CD8+ T cells (Fig-
ures S2A–S2F). Further, the number of T cells (CD4+ and CD8+
T cells combined) correlated with the presence of the T cell-re-
cruiting chemokine CXCL10 in BAL but not the lung interstitium,
suggesting recruitment of T cells to the alveolar space (Figures
S2G and S2H). Using quantitative immunohistochemistry, we
confirmed severe depletion of lung interstitial CD4+ T cells
in vivo (Figures 2G–2I). Given that CD4+ T cell loss in lung tis-
sue in vitro was accompanied by a high frequency of produc-
tively infected CD4+ T cells, we measured the HIV-1 viral
load in the lungs and spleens of HIV-1-infected humanized
mice. We observed that the viral load in total lung tissue was
significantly higher compared with the spleen 7 weeks after
infection (Figure 3A). Further, we also quantified viral RNA
from sorted CD4+ T cells and CD14+ monocytes from spleen
and lung tissue and found 5.5-fold more HIV-1 gag RNA in
lung versus spleen CD4+ T cells, whereas detection of viral
RNA from sorted monocytes was below the limit of detection
in most samples (Figure 3B). Additionally, we stained HIV-1
p24 protein in tissue sections and found a significantly higher
ratio of p24+:CD4+ cells in lung tissue sections compared
with the spleen (Figures 3C and 3D). Thus, HIV-1 infection in
humanized mice with a CCR5-tropic HIV-1 strain resulted in
high levels of productive infection and profound loss of CD4+
T cells in the lung interstitium, where depletion was more se-
vere than in the blood, spleen, and alveolar space.
CD45iv Lung Interstitial CD4+ T Cells Are Most
Significantly Depleted by HIV-1
CD4+ interstitial TRM-like cells are characterized by their effector
memory phenotype, expression of CD69, high expression of
CD11a, and their inaccessibility to antibodies in the circulation
introduced by intravenous injection (CD45iv) (Anderson et al.,
2014). To further differentiate resident interstitial versus vascular
CD4+ T cells in the lungs of the humanized mouse, we in vivo-
labeled vascular cells with an antibody binding to human CD45
3 min before sacrificing the mice and analyzed CD45iv CD4+
interstitial TRM-like cells by flow cytometry (Figure S3). Lung
T cells consisted of a CD45iv and CD45iv+ population,
whereas other compartments were primarily CD45iv (BAL
and spleen) or CD45iv+ (blood) (Figure 4A). CD45iv CD4+
T cells in the lungs showed significantly higher loss compared
with blood CD4+ T cell loss (Figure 4B). CD45iv and CD45iv+
lung CD4+ T cells had an increased frequency of memory
T cells and the lung recruiting chemokine receptor CXCR3 (Fig-
ures S4A and S4B). However, only lung interstitial CD45iv
CD4+ T cells had high expression of the TRM cell markers
CD69 (Figure 4C) and CD11a (Figure S4C) and showed higher
expression of the HIV-1 co-receptor CCR5 compared with
vascular CD45iv+ lung CD4+ T cells (Figure 4D). Furthermore,
lung CD45iv CD4+ T cells had the highest frequency of HIV-1
p24+ cells, and the number of lung interstitial CD45iv CD4+
T cells, but not blood CD4+ T cells, correlated with the frequency
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of HIV-1 p24+ CD4+ T cells (Figure S4D; Figures 4E and 4F).
Taken together, CD45 in vivo labeling revealed the presence
of a CD4+CD45ivCD45RO+CD62LCD69+CD11ahigh intersti-
tial TRM-like cell population in the lung, which demonstrated se-
vere depletion with HIV-1 infection that was not reflected by
sampling of cells in the alveolar space.
Mtb/SIV Co-infection in NHPs Leads to Severe CD4+
T Cell Depletion in the Lungs and Increased
Disseminated TB
Increased risk of ATB correlates with the loss of circulating CD4+
T cells during AIDS progression. However, HIV infection in-





Figure 2. HIV-1 Infection Results in Severe Depletion of Lung Interstitial CD4+ T Cells In Vivo
Humanized mice from 2 different batches were intravaginally infected with 50,000 infectious particles of HIV-1 (JR-CSF) (n = 14) or left uninfected as controls
(n = 13).
(A–D) 4 and 7 weeks after infection, cells from (A) the lung interstitium, (B) BAL, (C) the spleen, and (D) the blood were analyzed for CD4+ T cell loss by comparing
CD4+ T cell numbers with uninfected control animals using flow cytometry.
(E and F) CD4+ T cell loss in paired BAL and lung samples was analyzed as fold change compared with the median CD4+ T cell count of uninfected animals (E)
4 weeks or (F) 7 weeks after infection.
(G) Depletion of CD4+ T cells 7 weeks after infection in lungs compared with the spleen was confirmed by immunohistochemistry (IHC) staining for CD4.
(H and I) CD4+ cells in (H) the lungs and (I) the spleen were quantified using Histoquest software.
The p values were measured by Kruskal-Wallis and Dunn’s multiple comparisons tests and (H and I) Mann-Whitney U test. Scatterplots are labeled with median
and interquartile range. Each data point represents one humanized mouse sample.
See also Figure S2.
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the blood (Sonnenberg et al., 2005). We hypothesized that,
during early HIV-1 infection, lung interstitial CD4+ T cell loss is
associated with TB disease progression. The humanized mouse
is highly susceptible to even non-pathogenic mycobacterium
infection, and the generalizability of HIV-1-induced lung
interstitial CD4+ T cell depletion is unclear (Lee et al., 2013).
We therefore used the NHP Mtb/SIV co-infection model. NHPs
were infected with a low dose of Mtb CDC1551 to establish
LTBI 9 weeks before co-infecting a subgroup with SIVmac239
for 1113 weeks. SIV infection significantly increased reactiva-
tion of LTBI (Figure S5A). At the time of necropsy, the number
of bulk and effector memory lung interstitial CD4+ T cells was
significantly reduced (Figure 5A; Figure S5B), whereas CD4+
T cells in BAL, blood, bronchial lymph nodes (Br LNs), and the
spleen were not significantly decreased (Figures 5B and 5C; Fig-
ures S5C–S5F), consistent with our findings with human lung
tissue and humanized mice. Lung interstitial CD4+ T cell loss
was significantly higher compared with paired BAL samples
(Figure 5D), and BAL CD8+ T cell numbers showed a trend of
increased numbers in SIV-co-infected compared with SIV-
uninfected animals (Figure S5G).
Patients with clinical HIV-1/TB co-infection often present with
extrapulmonary TB (Lawn and Gupta-Wright, 2016). Because
CD4+ TRM-like cells have been described as important for con-
trol of pulmonary Mtb infection, we hypothesized that the early
loss of lung interstitial CD4+ T cells in NHPs latently infected
with Mtb would also contribute to the dissemination of Mtb to
other organs. We found an increased extrapulmonary Mtb
burden in SIV-infected animals compared with those that were
uninfected, with a significantly higher bacterial burden in the liver
A B
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Figure 3. CD4+ T Cells in the Lungs Are
Highly Susceptible to Productive HIV-1
Infection In Vivo
(A and B) 7 weeks after infection, RNA was ex-
tracted from lung and spleen (A) total tissue or (B)
from sorted CD4+ T cells from the lungs and
spleen. HIV-1 RNA was detected by HIV-1 gag
qPCR and quantified by using a linear HIV-1
standard and normalized to CD4+T cell counts.
(C and D) Production of virus in lung CD4+ cells
was confirmed by protein staining of HIV-1 p24
using IHC (C). The ratio of p24+ cells:CD4+ cells in
the lungs and spleen was quantified using Histo-
quest software (D).
The p values were measured by (A and D) Mann-
Whitney U test and (B) Kruskal-Wallis and Dunn’s
multiple comparisons tests. Scatterplots are
labeled with median and interquartile range. Each
data point represents one humanized mouse
sample.
(Figure 5E) and with similar trends for the
spleen and kidneys (Figures S5H and
S5I). Interestingly, decreasing lung inter-
stitial CD4+ T cell numbers significantly
correlated with Mtb burden in the liver
(Figure 5F) and spleen (Figure S5J) in
NHPs with LTBI. In comparison, BAL or
blood CD4+ T cells did not correlate with extrapulmonary burden
(Figures S5K and S5L). In summary, early SIV infection resulted
in severe depletion of lung interstitial CD4+ T cells but not those
in the alveoli. Importantly, this lung interstitial CD4+ T cell loss
was strongly associated with dissemination of pulmonary TB
before reactivation of LTBI.
DISCUSSION
HIV-1 primarily infects CD4+ T cells, which leads to the loss of
this important arm of the immune response and contributes to
increased susceptibility to opportunistic infections. Our study re-
vealed that, unlike CD4+ T cells in the alveolar space or circula-
tion, lung interstitial CD4+ T cells are severely depleted by HIV-1
early in infection in human lung tissue ex vivo, in humanized mice
in vivo, and by SIV in NHPs. HIV-1-induced lung interstitial CD4+
T cell depletion was accompanied by high virus production and
was rescued by ARVs or caspase-3 inhibition in vitro. Further,
CD45 in vivo labeling revealed that lung interstitial CD4+ TRM-
like cells showed the highest HIV-1 infection rates, which was
associated with their depletion. The severe loss of lung interstitial
CD4+ T cells in Mtb/SIV co-infected NHPs correlated strongly
with dissemination of Mtb into extrapulmonary organs.
Although mucosal CD4+ T cells in the intestinal tract have
been reported to be depleted early during infection with HIV-1
or SIV, the fate of lung interstitial CD4+ T cells has been less
well characterized. Here we describe early severe depletion of
lung interstitial CD4+ T cells in vitro and in vivo, induced by
HIV-1 in human cells and by SIV in NHPs. Previously, human
studies of lung CD4+ T cells in HIV-infected subjects have
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used BAL as a surrogate for interstitial tissue cells and have
suggested minimal or no depletion of CD4+ T cells in this
compartment (Brenchley et al., 2008; Bunjun et al., 2017; Mwale
et al., 2018). A study in NHPs reported transient BAL CD4+ T cell
depletion that was rapidly reversed by infiltrating CD4+ T cells
with increased anti-viral resistance (Verhoeven et al., 2014).
Our studies in the humanized mouse and NHPs allowed us to
simultaneously compare paired BAL and lung interstitial CD4+
T cells in vivo. Although BAL CD4+ T cells had a similar pheno-
type as lung interstitial T cells, the CD4+ T cell loss in BAL
compared with SIV-uninfected NHPs was more comparable
with the blood and spleen and consistent with the observations
in BAL from human cohort studies. It is possible that the lympho-
cytic infiltration into alveoli during HIV-1 infection that has been
described in humans and NHPs might compensate for CD4+
T cell loss. The observed differences in CD4+ T cell depletion
in the lung interstitium versus BAL highlights that sampling of
the alveolar space does not fully reflect HIV-1 infection of lung
interstitial CD4+ T cells. Therefore, our data suggest that the
severity of lung CD4+ T cell depletion has been underestimated,
with early and severe lung CD4+ T cells depletion similar to those
found in the gut.
Intestinal CCR5+ CD4+ effector memory T cells (TEM cells) are
a preferred target cell for HIV-1 replication in vivo (Dillon et al.,
2016; Mattapallil et al., 2005; Steele et al., 2014; Veazey et al.,
2000). We also found that enrichment of this cell type in the lungs
had consequences for their susceptibility to HIV-1 infection and
depletion. We showed that CCR5-tropic HIV-1 replication was
high in these cells in the lung in vitro, whereas CXCR4-tropic







Figure 4. CD69+ Memory CD45iv Lung Interstitial CD4+ T Cells Are Most Significantly Affected by HIV-1-Induced CD4+ T Cell Loss
HIV-1-infected humanized mice (n = 6) or uninfected control mice (n = 12) were labeled by injection of an anti-human CD45 antibody for 3 min prior to sacrifice.
CD45iv– and positive CD4+ T cells were analyzed in the lungs, BAL, spleen, and blood by flow cytometry.
(A) Representative plots of CD45iv+ and CD45iv CD4+ T cells in the lungs, BAL, spleen, and blood.
(B–D) The TRM-like phenotype of CD45iv+ or CD45iv CD4+ T cells was further characterized by flow cytometry.
(B) Fold lung CD4+T cell loss was analyzed by comparing CD4+ T cell numbers from infected with median uninfected control animals.
(C) The percentage of all CD4+ T cells with surface expression of CD69+ was analyzed by gating on viable CD4+ TCRa/b+CD45RO+CD62LCD25 T cells.
(D) The percentage of all CD4+ T cells with surface expression of CCR5+ was analyzed by gating on viable CD4+ T cells.
(E and F) Correlation between intracellular HIV-1 p24+ CD4+ T cells 4 weeks after infection and number of (E) lung CD45iv CD4+ T cell and (F) blood CD45iv+
CD4+ T cells.
The p values were measured by (A–D) Kruskal-Wallis and Dunn’s multiple comparisons tests and (E and F) Spearman test. Scatterplots are labeled with median
and interquartile range. Each data point represents one humanized mouse sample.
See also Figures S3 and S4.
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the high frequency of productively infected CD4+ T cells was
accompanied by severe CD4+ T cell loss. In contrast to mucosal
tissue, CXCR4-tropic HIV-1 preferentially infected CD4+ T cells
from SLOs, suggesting that viral replication at this site may be
more relevant during later stages of infection in patients where
the CXCR4-tropic virus has emerged (Doitsh et al., 2010; Glush-
akova et al., 1999; Grivel et al., 2007; Grivel et al., 2000a, 2000b).
Inhibition of viral replication by ARVs or by a caspase-3 inhibitor
was sufficient to completely rescue CD4+ T cell loss. Prior
reports support our finding that productive infection of CD4+
T cells activates caspase-3-mediated cell death, whereas in-
flammasome and caspase-1 activity cause CD4+ T cell death
during abortive infection (Badley et al., 2000; Doitsh et al.,
2010; Li et al., 2005). The caspase-1 pyroptosis pathway in
abortively infected cells was shown to be activated by the accu-
mulation of viral cDNA, and treatment with the integrase inhibitor
raltegravir did not rescueCD4+ T cell death (Monroe et al., 2014).
However, these studies were conducted with the CXCR4-tropic
virus and SLO-derived CD4+ T cells, which suggests that there
are important differences in the mechanism of cell death in
mucosal tissue versus SLOs. In contrast to SLOs, but similar to
lung tissue, CD4+ T cells in the intestinal tract are highly suscep-
tible to CCR5-tropic HIV-1 infection and HIV-1-mediated cell
death early during infection (Brenchley et al., 2004; Li et al.,
2005).
SIV infection in NHPs showed similar patterns for lung CD4+
T cell depletion as we observed for HIV-1 infection in lung
tissue. We extended our findings by using the experimental
NHP model for human LTBI to investigate the relevance of
CD4+ T cell depletion for dissemination of Mtb infection. The
NHP model reflects the high prevalence ofMtb/HIV-1 co-infec-
tion in sub-Saharan African countries, with the limitation that, in
Mtb/HIV-1 co-infected humans, re-infection is more likely than
reactivation (Andrews et al., 2012; Mahomed et al., 2011). We
found that SIV significantly induced reactivation of LTBI and
that, at the time of necropsy, only lung interstitial CD4+ T cell
were severely depleted. Our data suggest that, during early
viral infection, CD4+ T cells in BAL, circulation, and SLOs are
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Figure 5. Mtb/SIV Co-infection in NHPs Leads to Severe CD4+ T Cell Depletion in the Lung Interstitium, which Is Associated with Increased
Disseminated TB
Rhesus macaques were infected withMtb CDC1551 via low-dose aerosol challenge to establish LTBI (n = 26). 9 weeks afterMtb infection, a subset of the NHPs
(n = 15) was co-infected with SIVmac239. Necropsy was performed 20–22 weeks afterMtb infection or after TB reactivation with collection of the lungs, spleen,
kidneys, and liver. BAL was performed prior to necropsy.
(A–C) None of the SIV-uninfected animals progressed from LTBI (circles) to active tuberculosis (ATB; triangles), whereas 8 animals in the SIV-infected group
developed ATB. CD4+ T cell numbers in lung tissue (A), BAL (B), and blood (C) were assessed by flow cytometry.
(D) CD4+ T cell loss relative to the median in the CD4+ T cell count in SIV-uninfected NHPs in paired BAL and lung samples was determined.
(E)Mtb burden in the liver was measured in SIV-infected and uninfected NHPs, and lung interstitial CD4+ T cell numbers were correlated with liver CFUs/g tissue.
The p values weremeasured by (A–C and E) Mann-Whitney U test, (D) Wilcoxon test, or (F) Spearman r test. Scatterplots are labeled with median and interquartile
range. Each data point represents one NHP.
See also Figure S5.
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not significantly depleted and associated with ATB. The protec-
tive role of circulating CD4+ T cells in humans has been sup-
ported by the fact that ATB correlates with the decline of blood
CD4+ T cells during chronic HIV-1 (Lawn et al., 2009). However,
other reports have found that CD4+ T cells in the blood are not
directly associated with protection against ATB. Adoptive intra-
venous transfer ofMtb-specific CD4+ T cells into the circulation
of mice infected with Mtb for 1 week does not reduce the bac-
terial burden (Gallegos et al., 2008), and protection against ATB
in Bacillus Calmette Gue´rin (BCG)-vaccinated adolescents
does not correlate with circulating Mtb-specific CD4+ T cell
responses (Kagina et al., 2010). We also did not find that deple-
tion of lung interstitial CD4+ T cells correlated with reactivation
of LTBI. Therefore, although CD4+ T cells are important for a
protective immune response, reduced CD4+ T cell numbers
in the blood or the lung interstitium alone may not explain
increased susceptibility to TB inMtb/HIV-co-infected patients.
Location, phenotype, and their interaction with other cell types
are likely also important for their protective role (Foreman et al.,
2016; Sallin et al., 2017). However, our study is limited to
the role of CD4+ T cells in HIV-1-associated TB. HIV-1 impairs
other cell types, such as innate lymphoid cells, mucosa-associ-
ated invariant T cells, dendritic cells, and macrophages, which
might all contribute to increased susceptibility to TB (Diedrich
and Flynn, 2011; Kløverpris et al., 2016; Wong et al., 2013).
HIV-1 infection is associated with extrapulmonary TB. We
report that lung CD4+ T cell depletion correlated with extrapul-
monary Mtb burden in Mtb/SIV co-infection, suggesting that
lung interstitial CD4+ T cells are important for supporting a
localized immune response to prevent dissemination of Mtb.
We show an association between the severe loss of lung inter-
stitial CD4+ T cells and disseminated TB early in infection,
before loss of circulating CD4+ T cells. It has been reported
that lung Mtb-specific CD4+ T cells produce tumor necrosis
factor alpha (TNF-a), which is important in the maintenance of
granuloma structures and prevention of disseminated Mtb
(Lin et al., 2010). Whether specific SIV-mediated depletion of
lung interstitial TNF-a+ CD4+ T cells could be a potential mech-
anism for lung CD4+ T cell-associated extrapulmonary TB
should be further characterized.
In summary, HIV-1 and SIV infection of CD4+ T cells leads to
their severe depletion at mucosal sites. This has beenwell estab-
lished in the gut but less well characterized in the lung intersti-
tium. Our findings show a discordance between characterization
of the lung interstitium and alveoli following lentiviral infection.
This distinction is important in the context of Mtb co-infection
because CD4+ T cell loss in the lung interstitium, but not the alve-
olar space, is associated with extrapulmonary tuberculosis and
may help explain the high prevalence of disseminated TB even
in early HIV-1 infection.
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CCR5 BD Biosciences Cat# 300555; RRID: AB_2564390
HIV-1p24 Beckman Coulter Cat# 6604667; RRID: AB_1575989
CD4 BD Biosciences Cat# 550631; RRID: AB_393791
CD8 BD Biosciences Cat# 555369; RRID: AB_398595
CD3 BD Biosciences Cat# 557917; RRID: AB_396938
CD28 BD Biosciences Cat# 555726; RRID: AB_396069
CD95 BD Biosciences Cat# 555671; RRID: AB_396024
anti human CD4 Abcam Cat# ab67001; RRID: AB_1139906
Bacterial and Virus Strains
HIV-1 NL4-3 CCR5-tropic GFP Murooka et al., 2012 N/A
HIV-1 NL4-3 CXCR4-tropic GFP Murooka et al., 2012 N/A
HIV-1 JRCSF Boutwell et al., 2009 N/A
SIVmac239 Foreman et al., 2016 N/A
Mycobacterium tuberculosis CDC1551 Foreman et al., 2016 N/A
Biological Samples
Human PBMCs MGH blood donor center N/A
Tonsil tissue MGH Eye and Ear Infirmary N/A
Lung tissue MGH Pathology lab N/A
Chemicals, Peptides, and Recombinant Proteins
Histopaque 1077 Sigma Aldrich Cat# 10771
CD45 enrichment kit StemCell Cat# 18529
Live/Dead fixable Blue dead cell stain kit ThermoFisher Scientific Cat# L23105
HIV-1 p24 ELISA PerkinElmer Cat# NEK050B001KT
Maraviroc Sigma Aldrich Cat# PZ0002
AMD3100 Sigma Aldrich Cat# A5602
Zidovudine (AZT) Sigma Aldrich Cat# PHR1292
Efavirenz Sigma Aldrich Cat# SML0536
Raltegravir Santa Cruz Biotechnology Cat# CAS 871038-72-1
Darunavir Sigma Aldrich Cat# SML0937
(Continued on next page)
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CONTACT FOR REAGENT AND RESOURCE SHARING
Further information for reagents and resources can be addressed to and will be fulfilled by the Lead Contact, Dr. Bjӧrn Corleis
(bcorleis@mgh.harvard.edu).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Human subjects
All work involving material from human subjects was approved by the Institutional Review Board (IRB) at Massachusetts General
Hospital (MGH). For PBMCs, cells were isolated from buffy coats of anonymous healthy blood donors obtained from the MGH blood
donor center (Boston, MA) after approval by the Partners Human Research Committee under protocol 2005P001218. Tonsil and lung
tissue was received as excess tissue from the Pathology Departments of MGH and the operating room at theMassachusetts Eye and
Ear Infirmary (Table S1). Sex, age and post-operation diagnosis of patient samples are summarized in Table S1. The use of surgical
excess tissue was approved by the Partners HumanResearch Committee under the approved protocol # 2010P000632. Sample size
was based on feasibility and availability of human excess tissue collections. Donor matched controls were used for all experimental
conditions.
Humanized mouse
Humanizedmicewere purchased from theMGHHuman Immune SystemMouseCore (Boston, USA). All humanizedmouseworkwas
approved by the Institutional Animal Care and Use Committee (IACUC) at MGH under the protocol # 2009N000136 adhering to the
United States Animal Welfare Act and the Animal Welfare Regulations. Humanized mice were all female and 6-8 weeks of age during
engraftment of human tissue.
Non-human primates
Non-human primate experiments and procedures were approved by the Institutional Animal Care and Use Committee of Tulane Uni-
versity, New Orleans, LA, and were performed in accordance with NIH guidelines and under the protocols # PO295, PO295R,
PO247R, PO065, PO324 and P0095. For this study, we analyzed 26 specific pathogen-free, retrovirus-free, mycobacteria-naive,
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
Z-VAD-FMK R&D systems Cat# FMK001
Z-DEVD-FMK R&D systems Cat# FMK004
Z-WEHD-FMK R&D systems Cat# FMK002
Annexin-V buffer BD Biosciences Cat# 556454
Annexin-V APC BD Biosciences Cat# 550474
Fix & Perm buffer Life technology Cat# GAS003
progesteron (Depo-provera) Pfizer N/A
Critical Commercial Assays
RNAeasy microkit QIAGEN Cat# 74004
QuantiFAST SYBR green RT-PCR kit QIAGEN Cat# 204154
Experimental Models: Cell Lines
GHOST cell line NIH AIDS Research & Reference Reagent Program N/A
HEK293 T cell line NIH AIDS Research & Reference Reagent Program N/A
Experimental Models: Organisms/Strains
Humanized mouse MGH Human Immune system core N/A
Non-human primates Tulane National Primate Research Center N/A
Oligonucleotides
HIV-1 gag forward AGTGGGGGGACATCAAGCAGCCATGCAAAT Boutwell et al., 2013
HIV-1 gag reverse TGCTATGTCACTTCCCCTTGGTTCTCT Boutwell et al., 2013
Software and Algorithms
GraphPad Prism7 Graphpad software N/A
Flow Jo Vx0.7 FlowJo, LLC N/A
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male, adult Indian rhesus macaques (NHPs) between the ages of 3-12 years that were bred and housed at the Tulane National
Primate Research Center (TNPRC). NHPs were pair-housed during the duration of the study. Additional analysis has been performed
using experimental data originally generated in a prior study of SIV infected animals (Foreman et al., 2016), as well as additional an-
imals (Table S2).
Cell lines
The human female kidney cell line, HEK293 (Graham et al., 1977), first isolated fromprimary embryonic kidney tissue and transformed
by sheared human adenovirus type 5 (Ad5DNA) and the human osteosarcoma cell line, GHOSTCXCR4+CCR5+ (Mo¨rner et al., 1999),
first isolated from human osteosarcoma cells of unknown sex which were stably transduced with a MV7neo-T4 vector, the MLV-
CCR5 BABE-puro vector, the MX-CCR4 and MX-CCR5 vector and cotransfected with HIV-2 LTR-GFP, were obtained from the
NIH AIDS Reagent Program. Cells were maintained in DMSO (GIBCO) supplemented with 10% (v/v) FCS (Sigma), 2 mM Glutamine
(Corning), 100 I.U./ml penicillin (Corning) and 100 I.U./ml streptomycin (Corning). GHOSTCXCR4+CCR5+ cell cultureswere addition-
ally supplemented with 100 mg/ml hygromycin (Corning) and 1 mg/ml puromycin (Corning).
METHOD DETAILS
Human blood and tissue samples
PBMCswere separated by centrifugation on a histopaque gradient and used fresh. In all cases, we receivedmacroscopically healthy
disease-free tissue sections that were further examined by a pathologist in frozen sections and found to be histologically normal.
Human tissue was processed fresh and at 4C. Blood contamination of tissues was minimized by exclusion of tissue sections which
demonstrated significant blood contamination by gross pathological examination. Further, tissues were washed 3 times with FACS
buffer (PBS+1%FCS+5mM EDTA). Fresh single cell suspensions from lung and tonsil tissue were made by mechanically disrupting
dissected tissue using a cell strainer and a 10mL syringe plunger. Frequency of CD45+ leukocytes was high in tonsil (> 98%), but low
in whole lung single cell suspension (1%–2%). Therefore, lung CD45+ leukocytes were enriched from whole lung tissue single
suspension using a CD45 enrichment kit (Stemcell) for magnetic-activated cell sorting (MACS) according to the manufacturer’s in-
structions. Blood or tissue single cell suspensions were collected in R10 (RPMI (Sigma), 10% (v/v) FCS (Sigma), 2 mM Glutamine
(Corning), 100 I.U./ml penicillin (Corning) and 100 I.U./ml streptomycin (Corning)) and used for further studies.
HIV-1 in vitro infection assay
HIV-1 NL4-3 CCR5-tropic, CXCR4-tropic GFP or JR-CSF HIV-1 virus was used for all in vitro experiments. The plasmids were kindly
provided by ThomasMurooka and Thorsten Mempel (Murooka et al., 2012). For production of HIV-1, viral plasmids were transfected
together with FuGENE-6 (Polysience) into HEK293 cells and incubated overnight at 37Cand 5%CO2. Cell culture supernatants were
removed and replaced with fresh media for 48h under the same culture conditions. Cell culture supernatants were harvested and
centrifuged at 500xg for 10min at 4C. Supernatants were aliquoted and frozen down at-80C until further usage.Mock supernatants
were prepared under the same protocol without the addition of viral plasmids during the transfection steps. Titer of HIV-1 NL4-3 in-
fectious particles (i.p.)/ml was determined by infection of CD4, CCR5, and CXCR4 expressing GHOST cells (NIH AIDS Research &
Reference Reagent Program) (Kwon et al., 2002). Additionally, HIV-1 p24 protein levels were determined by ELISA (PerkinElmer)
following the manufacturer’s instructions. A viral stock with a titer of 2x106 i.p./ml (1.9x106 pg/ml p24gag protein) was used for all ex-
periments. 0.5x106 human leukocytes from blood, tonsil or lung cells were mixed with 0.1x106 infectious viral particles (MOI =
0.2 equivalent to 95ng p24gag) in a 96 well V-bottomed polystyrene plate in a total volume of 100 mL and kept at 4C.Where indicated,
cells were pre-incubated with anti-retroviral drugs or chemical inhibitors for 30 min at 37C before infection and were consistently
present throughout the experiment. Leukocyte/HIV cultureswere spin-infected for 90min at 4Cand 800 x g andwere then incubated
at 37C for 12 hr. Supernatants containing cell free virus were taken off and replaced with fresh media. Cells were harvested after
96 hr to analyze the number of live CD4+ T cells and the percentage of virus producing GFP+ cells. ART drugs were all purchased
from Sigma-Aldrich and used at the following effective and nontoxic concentrations: 40 mM maraviroc (MVA), 250 nM AMD3100
(AMD), 10 mM Zidovudine (AZT), 100 nM Efavirenz (EFV), 12.5 nM Raltegravir (RAL), and 25 nM Darunavir (DRV). For inhibition of
caspase activity, the following chemical inhibitors from R&D systems were used at a concentration of 10 mM: pan-caspase inhibitor
Z-VAD-FMK, caspase 3 inhibitor Z-DEVD-FMK, and caspase 1 inhibitor Z-WEHD-FMK.
Flow cytometry
Human cells from ex vivo or in vivo experiments were resuspended in FACS buffer (PBS+1%FCS+5mM EDTA) and centrifuged for
5 min at 1500 x g at 4C. Cell pellets were stained with antibodies against cell surface antigens and with blue or green viability dye
(Invitrogen fixable viability dye) to exclude dead cells from analysis, for 20 min at room temperature (RT). Details for all specific and
titrated monoclonal antibodies are listed in the resource table. For analysis of T cells in human and humanized mouse samples, cell
pellets were stained with anti CD45 (HI30), CD3 (UCHT1), CD4 (RPA-T4) and CD8 (HIT8a). Tissue resident CD4+ T cells were as-
sessed by incubating cells with antibodies binding to TCRab (IP26), CD103 (Ber-ACT8), CD25 (2A3), CD69 (FN50), CD62L
(DREG-56), CXCR3 (G025H7), CD45RO (UCHL1), and CD11a (HI111). HIV-1 co-receptor expression was analyzed using an antibody
detecting humanCCR5 (2D7/CCR5). Memory CD4+ T cells in NHPswere defined using anti CD95 (DX2) and anti CD28 (CD28.2), with
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effector memory (TEM) CD4+ T cells CD95+CD28- and central memory (TCM) CD4+ T cells CD95+CD28+. For detection of apoptotic
cells, all washing steps were performed in Annexin-V washing buffer (BD Bioscience), before and after staining with Annexin V-APC
(BD Bioscience) for 10 min at RT. Cells were stained for intracellular HIV-1 gag p24 by incubating cells with fixation/permeabilization
buffer A (Invitrogen) for 20 min at RT, followed by a washing step with PBS and addition of perm/fix buffer B (Invitrogen) for 15 min at
RT. HIV-1 infected cells were stained with an antibody binding HIV p24 (KC57) and incubated for 30 min at 4C. Cells were fixed with
2% PFA before running on a LSR Fortessa flow cytometer (BD Biosciences) within 4 hr, or immediately in case of Annexin-V stained
samples. Flow data were analyzed with FlowJo (TreeStar). Countbright beads (Invitrogen) were added to calculate total CD4+ T cells
in lung, tonsil and PBMCs samples following the manufacturer’s instructions.
HIV-1 in vivo humanized mouse infection
JR-CSF HIV-1, was purchased from the virology core at the Ragon Institute of MGH, MIT and Harvard and was used for experiments
in the humanized mouse as described (Boutwell et al., 2009). Bone marrow/Liver/Thymus (BLT) humanized were purchased from the
MGH Human Immune System Mouse Core (HISMC, Boston, USA) as described in the ethical statement. Six to 8 weeks old female
BLT-NOD-scid IL2Rg/ (NSG) mice (The Jackson Laboratory) were housed in a pathogen-free facility at MGH, and reconstituted
with human tissue by the HISMC as described previously (Deruaz et al., 2017). BLT-NSGmice were obtained after successful human
immune cell reconstitution (> 40% of lymphocytes were human CD45+ of which > 30% of were CD3+ and a minimum of > 200 CD4+
T cells/uL) 13-18weeks post-surgery. A total of 34 humanized BLT-NSGmice from 2 different batches generated with different donor
tissues were used. One mouse was excluded from the analysis due to the development of severe graft versus host disease (GvHD)
during the experiment. Mice were infected with atraumatic intravaginal (IVAG) application of 0.5x105 TCID50 HIV-1JRCSF in 10-20 ml
PBS as previously described (Deruaz et al., 2017).Micewere treated 5 days prior to challengewith a subcutaneous injection of 200 mg
of progesterone (Depo-Provera medroxyprogesterone acetate, Pfizer) in a total volume of 100 ml of PBS. HIV-1 JRCSF infected mice
and uninfected control mice were euthanized 4 or 7 weeks post infection. Intravascular staining of human CD45+ cells was adopted
from (Anderson et al., 2014). For this, 3 mg of anti-human CD45 v500 (clone HI100, Biolegend) were injected i.v. in a total volume of
200 mL PBS. 3 min after antibody injection, the animals were euthanized. The method allows to distinguish lung vascular from inter-
stitial and alveolar CD4+ T cells. Since the number of interstitial CD4+ T cells exceeds the number alveolar CD4+ T cells, we defined
CD45iv- cells as interstitial CD4+ T cells. The following samples were collected: BAL, lung, spleen, and blood. BAL was obtained by
injection and recovery of 1 mL PBS through the trachea. Single cell suspensions from spleen and lung tissues were obtained as
described for human surgical tissue. The post-caval lobe of the lung was reserved for immunohistochemistry and placed in 10%
formalin. The right middle lobe was stored at80C in RNAlater and reserved for HIV-1 RNA extraction. Similar proportions of spleen
tissue were processed the same way.
HIV-1 gag RNA reverse transcriptase quantitative PCR (RT-qPCR)
RNA was extracted from homogenized tissue and sorted cell populations using the RNAeasy kit (QIAGEN) following the manufac-
turer’s protocol. RNA was resuspended in RNase free water and stored in aliquots at 80C. RT-qPCR was performed using
HIV-1 gag-specific primers (SK145 forward, AGTGGGGGGACATCAAGCAGCATGCAAAT and SK431 reverse, TGCTATGTC
ACTTCCCCTTGGTTCTCT), quantified using the QuantiTect SYBR green RT-PCR kit (QIAGEN) according to the manufacturer’s in-
structions and using a Roche 384 well plate Lightcycler 480-II (Roche). Concentrations of HIV-1 gag RNA were calculated from a
linear gag HIV-1 HxB2 standard kindly provided by Dr. Christian Boutwell (Boutwell et al., 2009). Results were normalized for tissue
weight (in ng) or total cell numbers for tissue samples and sorted cells, respectively.
Immunohistochemistry
Formalin fixed, paraffin embedded tissue from lung and spleen samples of HIV-1 infected and uninfected mice were cut in 4 mm sec-
tions. Antigen retrieval was carried out in a Decloaking Chamber (BioCare Medical), in citrate buffer pH 6 (Invitrogen). Sections were
incubated with anti-HIV-1 p24 (1:50; clone KC57 BeckmanCoulter) or anti-humanCD4 (1:50; clone 1F6 Abcam) antibody overnight at
4C. Slides werewashed five times in Tris buffered saline with 0.05%Tween-20 (TBST). Secondary anti-mouse HRP conjugated anti-
body (Dako) was applied for 1 hr at RT. After another five washes with TBST, staining was visualized using DAB substrate (Dako).
Tissue samples were counterstained with Harris Modified Hematoxylin (Sigma). Whole tissue slide sections were scanned with an
Olympus TissueFAXSwhole slide scanning system and the number of p24+ or CD4+ cells were quantified using HistoQuest software
(TissueGnostics) and by taking the average of 2 consecutive tissue sections from per sample. Background was subtracted for each
sample by staining 2 consecutive tissue sections without the addition of the secondary antibody. The average number of unspecific
stained cells from 2 slides were subtracted from the average number of CD4+ or p24+ cells.
Mycobacterium tuberculosis / SIV infection in nonhuman primates
We retrospectively analyzed and compared CD4+ T cells in the lung and blood of SIV uninfected versus SIV infected animals (Table
S2). The experiment and data collection were performed as following and described previously (Foreman et al., 2016). All animals
were aerosol exposed to a low dose (10-25 CFU implanted) of Mtb CDC1551 and after maintenance of LTBI for up to 9 weeks,
a subset of 15 of the macaques was co-infected with 300 TCID50 of SIVmac239 administered intravenously, as described previously
(Foreman et al., 2016, 2017; Kuroda et al., 2018; Mehra et al., 2011). Group distributions were assigned based on clinical outcomes
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duringMtb andMtb/SIV co-infection. LTBI in NHPs was defined as asymptomatic without clinical signs for the duration of the study
and as described previously (Mothe´ et al., 2015). Criteria for active tuberculosis (reactivation) during the study were described before
(Foreman et al., 2016) and included Mtb culture positive BAL, chest X-ray, body temperature, weight, and maintenance of a CRP
value above 3 mg/mL or more for 3 consecutive weeks. Early animal euthanasia due to discomfort, were performed as previously
described (Foreman et al., 2016). Clinical assessments and lung pathology post-necropsy (% lung involvement) were performed
by veterinary clinicians in a blinded fashion and previously described (Foreman et al., 2016; Kaushal et al., 2015). BAL samples
were obtained by bronchoscopy before necropsy, and total cell numbers and T cell phenotypes were assessed in 1/20 of the recov-
ered BAL volume by flow cytometry. Necropsy was performed 20-22weeks post-Mtb infection. Lung, spleen, bronchial lymph nodes
(Br LN), kidney and liver tissues were collected and processed with bacterial load analyzed by colony forming unit assay (CFU) as
described (Foreman et al., 2016; Mehra et al., 2011, 2015). CD4+ and CD8+ T cell numbers were analyzed in 1x106 total tissue cells
or 100 mL of whole EDTA blood by flow cytometry using anti-human or anti-NHPs antibodies against CD4 (L200), CD8 (RPA-T8), CD3
(SP34-2), CD28 (CD28.2), CD95 (DX2).
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical details of experiments can be found in each figure legend. Nonparametric tests were used to compare medians between
groups. The Mann-Whitney test was used for 2 groups and the Kruskal-Wallis test followed by Dunn’s multiple comparison post
test was used for > 2 groups. Wilcoxon signed rank was used to compare continuous data between two time points. Spearman’s
correlation coefficients were used to examine associations between variables. Differences were considered significant at
p < 0.05. Prism 7 (Graphpad) was used for all analyses.
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Figure S1. Depletion of lung CD4+ T cells is associated with productively infected cells. Related to Figure 1. 
Isolation of cells and infection with HIV-1 was performed as described in Figure 1. (A and B) Total cell counts of (A) 
CD4+ and (B) CD8+ T cells was analyzed by flow cytometry in paired samples mock infected or infected with CCR5-
tropic HIV-1. Blood, tonsil or lung cells were infected with CXCR4-tropic NL4-3 GFP HIV-1, mock infected or left 
untreated. Where indicated, cells were incubated with the CXCR4 antagonist plerixafor (AMD3100) before infection. 
(C). Percentage of viable CD4+ T cells (D) was determined relative to untreated cells by flow cytometry. (E) Analysis 
of CCR5-tropic HIV-1 GFP+ CD4+ T cells from samples analyzed for viable CD4+ T cells in Figure 1F. (F) Lung 
cells were pre-incubated with the CCR5 antagonist maraviroc [MVA], the pan-caspase inhibitor Z-VAD-FMK [pan-
CASP], the caspase 3 inhibitor Z-DEVD-FMK [CASP3], or the caspase-1 inhibitor Z-WEHD-FMK [CASP1] before 
infection with HIV-1 as described in Figure 1, and CD4+ T cells were analyzed for viabilty by flow cytometry. (G 
and H) CXCL10 and IL1  protein level in cell culture supernatants were analyzed using the Luminex multiplex 
platform. p-value was measured by (A and B) Wilcoxon test or (C-H) Kruskal Wallis and Dunn’s multiple 





Figure S2. CD8+ T cells are increased in BAL compared to lung tissue. Related to Figure 2. The same batch of 
mice described in Figure 2 was analyzed for CD8+ T cell numbers in (A) lung, (B) BAL, (C) spleen and (D) blood by 
flow cytometry. (E and F) CD8+ T cell increases in paired BAL and lung samples were analyzed as fold increase 
compared to the median CD8+ T cell count of uninfected animals at (E) 4 weeks or (F) 7 weeks post infection. The 
CD8 T cell recruiting chemokine CXCL10 was measured by Luminex in BAL fluid 9G) or supernatants from lung 
tissue single cell suspensions (H) in samples obtained 4 weeks post infection. p-value was measured by (A-D) Kruskal 
Wallis and Dunn’s multiple comparisons test, (E and F) Wilcoxon test or (G and H) by Spearman r test. Scatter plots 





Figure S3. Gating strategy for CD4+ TRM-like cells by flow cytometry. Related to Figure 4.  Representative gating 
strategy for TRM-like cells in humanized mouse lung tissue. Gating started on positive selection of the lymphocyte 
population by SSC/FSC. Viable T cells were selected by gating on CD3+ fixable cell death dye- lymphocytes. Lung 
parenchyma CD4+ T cells were separated from lung vascular CD4+ T cells by anti-human CD45 in vivo labeling of 
circulating cells 3 min before sacrificing the humanized mice.  This resulted in CD3+ populations which were either 
CD45iv- or CD45iv+. Next, CD45iv- and CD45iv+ were separated into CD4+ and CD8+ T cells. CD4+ T cells were 
positively selected for memory cells by CD45RO+ and innate-like γδ T cells were excluded by positive selection of 
TCRαβ expressing CD45RO+ CD4+ T cells. Central memory and activated CD4+ T cells were excluded by negative 
selection of CD62L- and CD25- CD45RO+ CD4+ T cells, respectively. CD4+ TRM cells were defined as viable CD3+ 





Figure S4. Characterization of lung interstitium CD4+ T cells by flow cytometry. Related to Figure 4. HIV-1 
infected (4 weeks) humanized mice (n=6) or uninfected control mice (n=12) were iv injected with an anti-human 
CD45 antibody 3 mins prior to sacrifice. CD45iv negative and positive CD4+ T cells were analyzed in lung, BAL, 
spleen and blood by flow cytometry (see Figure S3 for gating strategy). The TRM phenotype of CD45iv labeled (lung 
iv+) or unlabeled CD45iv (lung iv-) CD4+ T cells was further characterized by flow cytometry. Percentage of all 
CD4+ T cells with (A) surface expression of CXCR3+ and (B) expression memory CD4+ T cell markers 
(CD45RO+CD62L-) was determined. (C) The median fluorescence intensity (MFI) of CD11a was analyzed. CD4+ T 
cells were gated on viable CD4+ TCRα/β+CD45RO+CD62L-CD25- T cells. (D) In vivo productively infected CD4+ 
T cells were analyzed by intracellular staining for HIV-1 p24+ and gating on all viable CD4+ T cells. p-value was 








Figure S5. SIV/Mtb co-infection leads to increased development of active and disseminated tuberculosis. 
Related to Figure 5. (A) 26 NHPs were infected with Mtb resulting in LTBI. After 9 weeks 15 NHPs were co-infected 
with SIV. 8 Mtb/SIV co-infected and 0 Mtb infected animals progressed to ATB. (B-F) CD4+ T cell loss in different 
compartments was analyzed in NHPs with LTBI or ATB by flow cytometry. (B and D) Cells were additionally stained 
with CD28 and CD95 and effector memory CD4+ T cells were defined as CD28-CD95+ (G) CD8+ T cells in BAL 
were analyzed in Mtb/SIV co-infected and Mtb infected NHPs by flow cytometry. Mtb burden was determined in (H) 
spleen and (I) kidney by CFU. Correlation of (J) spleen Mtb bacterial burden versus lung parenchymal CD4+ T cells 
and (K) liver bacterial burden versus BAL CD4+ T cells or (L) blood CD4+ T cells. p-value was measured by (A) 
Fisher’s exact, (B and D-I) Mann-Whitney U-test, (C) Kruskal Wallis with Dunn’s multiple comparisons test, or (J-






Table S1. Demographics and post-operative diagnosis of patient samples used for excess tissue experiments. 






Type Age Sex Post-Op Diagnosis 
LU1631 11/23/2015 Lung 70 Male Lung hamartoma 
LU1632 12/2/2015 Lung 68 Female Left upper lobe adenocarcinoma 
LU1637 12/11/2015 Lung 77 Female Squamous cell carcinoma of the lung 
LU1638 12/14/2015 Lung 52 Male Unknown source of hemoptysis 
LU1639 12/16/2015 Lung 37 Male Carcinoid tumor of right lower lobe 
LU1643 1/4/2016 Lung 60 Female Adenocarcinoma of the lung 
LU1654 2/1/2016 Lung 65 Female Adenocarcinoma of the lung 
LU1660 2/11/2016 Lung 65 Male Left local lobe adenocarcinoma 
LU1676 3/4/2016 Lung 76 Male Left upper lobe lung cancer 
LU1695 3/29/2016 Lung 65 Female Left upper lobe lung cancer 
LU1703 4/27/2016 Lung 43 Female Right lower lobe adenocarcinoma 
LU1705 5/2/2016 Lung 75 Female Lung carcinoma 
LU1708 5/16/2016 Lung 65 Male Adenocarcinoma, left lower lobe 
LU1711 5/20/2016 Lung 67 Female Right upper lobe nodule 
LU1712 5/20/2016 Lung 69 Male Ground-glass nodule, left upper lobe 
LU1715 5/31/2016 Lung 70 Male Lung carcinoma 
LU1735 7/14/2016 Lung 70 Female Right upper lobe lung cancer 
LU1746 7/25/2016 Lung 69 Female Adenocarcinoma, right lower lobe of lung 
LU1749 8/1/2016 Lung 36 Male Non-small cell lung cancer, left lung 
LU1752 8/9/2016 Lung 73 Female 
Mucinous cystic mass of the left lower lobe of 
the lung 
LU1767 9/7/2016 Lung 55 Male Probable lymphoma of lung 
LU1807 10/11/2016 Lung 85 Male Adenocarcinoma, left lower lobe of lung  
LU1821 10/19/2016 Lung 64 Female Metastatic sarcoma to left upper lobe of lung 
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LU1837 10/31/2016 Lung 56 Female Right lower lobe lung carcinoma 
LU1842 11/3/2016 Lung 60 Female Left lower lobe lung cancer 
LU1905 1/20/2017 Lung 72 Female Left lung cancer 
LU1926 2/3/2017 Lung 56 Female Metastatic colon cancer to right upper lobe 
LU1936 2/13/2017 Lung 79 Female Lung carcinoma 
LU1939 2/15/2017 Lung 44 Male 
Metastatic renal cell cancer to left upper lobe 
of lung 
TN1724 6/17/2016 Tonsil 3 Male 
Adenotonsillar hypertrophy and sleep 
disordered breathing  
TN1750  8/5/2016 Tonsil 5 Male 
Sleep-disordered breathing; Adenotonsillar 
hypertrophy 
TN1771 9/9/2016 Tonsil 3 Female 
Sleep-disordered breathing; Adenotonsillar 
hypertrophy 
TN1772 9/9/2016 Tonsil 4 Male Adenotonsillar hypertrophy 
TN1812 10/14/2016 Tonsil 3 Male 
Sleep disorder breathing; Adenotonsillar 
hypertrophy  
TN1813 10/14/2016 Tonsil 4 Female Sleep-disordered breathing 
TN1814 10/14/2016 Tonsil 6 Female Recurrent strep pharyngitis  
TN1869 12/2/2016 Tonsil 3 Female 
Adenotonsillar hypertrophy and sleep 
disordered breathing 
TN1870 12/2/2016 Tonsil 9 Male Adenotonsillar hypertrophy  
TN1882 12/2/2016 Tonsil 9 Male Adenotonsillar hypertrophy  
TN1887 12/2/2016 Tonsil 9 Male Adenotonsillar hypertrophy  






Table S2. Overview non-human primates used in this study. Related to Figure 5. 
Animal TB Status SIV Status Reference 
FE10 LTBI negative Foreman et al 2016 
FJ05 LTBI negative Foreman et al 2016 
GP50 LTBI negative unpublished 
HA90 LTBI negative Foreman et al 2016 
HB74 LTBI negative Foreman et al 2016 
HC90 LTBI negative Foreman et al 2016 
HV02 LTBI negative unpublished 
JD72 LTBI negative unpublished 
JF47 LTBI negative unpublished 
JK54 LTBI negative unpublished 
JN75 LTBI negative unpublished 
EH92 LTBI positive unpublished 
HP22 LTBI positive Foreman et al 2016 
HP41 LTBI positive Foreman et al 2016 
ID91 LTBI positive Foreman et al 2016 
IF04 LTBI positive unpublished 
IP88 LTBI positive unpublished 
JE48 LTBI positive unpublished 
KG40 LTBI positive unpublished 
ER44 ATB positive Foreman et al 2016 
HB12 ATB positive Foreman et al 2016 
HV08 ATB positive Foreman et al 2016 
ID01 ATB positive Foreman et al 2016 
JF23 ATB positive unpublished 
JH07 ATB positive unpublished 
JI68 ATB positive unpublished 
 
 
 
 
